Redhill Biopharma shares jump 45.37% premarket after securing $10.5 million court judgment against Kukbo.

Redhill Biopharma surged 45.37% in premarket trading following a landmark legal victory against Kukbo Co. Ltd. The New York Supreme Court’s final and enforceable judgment awarded RedHill over $10.5 million, including $8.6 million in the main ruling and $1.9 million for legal fees, with 9% annual interest accruing. The decision, now eligible for foreign recognition, also includes a Korean court attachment to prevent Kukbo from liquidating assets. This enforceable judgment, coupled with the company’s robust pipeline of late-stage drug candidates, signaled improved financial and strategic positioning, driving the sharp premarket gain.